intestinal peptide FAQ

Verify peptide reconstitution pH (must be 7.0–7.4) and confirm the dose matches published protocols. VIP's effective concentration range in smooth muscle assays is typically 10⁻⁹ to 10⁻⁷ M. Concentrations below this threshold won't saturate VPAC receptors; concentrations above 10⁻⁶ M can cause receptor desensitization. If pH or dosing is correct, the peptide itself may be degraded. Request a certificate of analysis from your supplier showing >98% purity via HPLC. Some research models require co-administration of peptidase inhibitors (e.g., aprotinin) to prevent VIP degradation in biological media.

VIP isn't inherently 'better' than other immune-modulating peptides like thymosin alpha-1 or BPC-157. It addresses different pathways. VIP suppresses pro-inflammatory cytokines through VPAC receptor activation, while thymosin alpha-1 enhances T-cell maturation and BPC-157 accelerates tissue repair through angiogenesis. The correct peptide depends on the biological question. If the goal is circadian regulation or bronchodilation, VIP is uniquely suited. For wound healing or gut repair, other peptides offer more targeted mechanisms.

That would be an error. Contact the supplier for clarification. No legitimate peptide supplier sells 'VIP' and 'vasoactive intestinal peptide' as distinct products because they're the same molecule. If a catalog lists them separately with different CAS numbers, SKU codes, or pricing, one entry is mislabeled. At Real Peptides, we use a single SKU for VIP with both the acronym and full name in the product description to avoid this exact confusion.

Discard the vial and reconstitute a fresh aliquot. VIP undergoes N-terminal peptidase cleavage at room temperature, losing 70–90% of receptor binding affinity within 24 hours. The degraded peptide fragments can still bind to VPAC receptors but act as partial agonists with unpredictable efficacy. Unlike some peptides where potency gradually declines, VIP's structural integrity is binary. It either maintains full activity (when frozen) or rapidly degrades into inactive fragments (at ambient temperature). No visual inspection can confirm whether VIP has degraded; only HPLC analysis detects truncated sequences.

Context clues tell you immediately. If the paper discusses neuropeptides, immune modulation, circadian rhythms, or VPAC receptors, 'VIP' definitively means vasoactive intestinal peptide. If the paper is outside biomedical research (business, hospitality, event planning), 'VIP' likely means something else. In our experience reviewing thousands of peptide research protocols, 'VIP' in a biological sciences context has never referred to anything other than vasoactive intestinal peptide.

Discard it. VIP degrades rapidly above refrigeration temperatures. Even a few hours at ambient temperature during shipping can hydrolyze peptide bonds and fragment the molecule. There's no reliable at-home test to confirm potency after a temperature excursion. Mass spectrometry analysis post-degradation typically shows molecular weights 200–600 Da below the expected range, indicating truncated peptides. Contact the supplier for replacement under proper cold-chain conditions or source from a provider with validated cold shipping protocols.

If your peptide is labeled 'VIP' instead of the full 'vasoactive intestinal peptide' name. Or vice versa. Verify the molecular weight on the certificate of analysis matches 3326.77 Da and the amino acid sequence is correct. The label terminology doesn't matter; sequence accuracy does. If no COA is provided, request one before use. A supplier unwilling to share analytical data is a supplier to avoid. Peptide identity can't be assumed from label text alone.

No. It's the same molecule. 'VIP peptide' is redundant phrasing (VIP already stands for 'vasoactive intestinal peptide'), but suppliers sometimes write it that way for clarity or SEO purposes. The peptide sequence, purity, and function are identical whether the label says 'VIP', 'VIP peptide', or 'Vasoactive Intestinal Peptide'. What matters is the Certificate of Analysis (CoA) showing purity ≥98% and correct mass spectrometry confirmation. Not the product name.

Use a purpose-built peptide cooler with phase-change gel packs that maintain 2–8°C for 36–48 hours. Standard ice packs cause temperature fluctuations as they melt; phase-change materials hold steady at refrigeration temperature. For air travel, pack lyophilized (unreconstituted) VIP in checked luggage with cooling packs. Lyophilized peptides tolerate short-term ambient exposure (up to 48 hours at 25°C) better than reconstituted solutions. Once reconstituted, VIP must remain refrigerated continuously; even a two-hour temperature excursion during shipping can cause partial degradation that reduces potency by 30–50%.

Selective VPAC1 or VPAC2 agonists allow isolation of receptor-specific pathways. VPAC1-selective analogs target immune modulation without altering circadian timing, while VPAC2-selective compounds regulate metabolic rhythm without broad immunosuppression. Researchers studying immune pathways often combine VIP analogs with compounds like Thymalin to explore complementary immune regulation mechanisms. Antagonist studies using receptor-blocking antibodies confirm pathway specificity.

Systemic VIP administration (intravenous) produces widespread vasodilation and transient hypotension due to smooth muscle VPAC1 activation, limiting therapeutic use. Localized delivery. Inhaled for pulmonary applications, intranasal for CNS targeting, or direct mucosal application for gut disorders. Achieves high tissue concentrations with minimal systemic effects. Inhaled VIP reaches intestinal mucosa via portal circulation, providing targeted anti-inflammatory effects in IBD without cardiovascular side effects.

Reduced VIP production or receptor expression correlates with chronic inflammatory states, circadian rhythm disorders, and impaired gut-brain signaling. Patients with inflammatory bowel disease show significantly lower VIP concentrations in intestinal mucosa compared to healthy controls, contributing to sustained Th1-driven inflammation and loss of mucosal barrier integrity. Circadian disruption from shift work or jet lag suppresses VIP expression in SCN neurons, desynchronizing peripheral metabolic clocks and increasing risk of metabolic syndrome.

Run a standard curve with positive control peptides to rule out assay-related issues first. If the assay system functions correctly with other VPAC1 agonists but VIP shows reduced or absent cAMP accumulation, the peptide likely suffered structural damage during storage or reconstitution. VIP aggregation, oxidation, or incorrect disulfide bonding all reduce receptor-binding affinity without visible changes to solution appearance. Request analytical documentation from your supplier showing HPLC purity and mass spectrometry data for the specific lot you received. If the supplier cannot provide batch-specific data, the peptide provenance is uncertain. Switch to a new vial stored continuously at −20°C, reconstitute with pH 7.0–7.4 buffer immediately before use, and repeat the assay. Persistent failure across multiple vials indicates supplier synthesis or quality control issues, not experimental error.

Discard it immediately and request batch analysis documentation from your supplier. VIP degradation produces peptide fragments that may still bind VPAC receptors with altered affinity or duration, generating inconsistent results that invalidate comparative studies. Visual inspection is insufficient. Degraded VIP often remains clear and colorless. The only reliable quality verification is HPLC (high-performance liquid chromatography) purity analysis showing >98% intact peptide at time of use. If you're conducting dose-response studies and suspect degradation mid-protocol, frozen aliquots from the original batch allow you to verify whether the experimental variable is VIP dose or VIP quality.

Consider co-administration with a DPP-4 inhibitor like sitagliptin to reduce enzymatic degradation, which can extend effective VIP half-life from 2 minutes to 8–12 minutes in some models. This approach is common in metabolic peptide research (GLP-1, GIP) but less documented for VIP. You'll need to establish pharmacokinetic curves in your specific model organism. Alternatively, switch to a modified VIP analog with built-in protease resistance, though this introduces structural variables that may alter receptor selectivity. The choice depends on whether your research question requires native VIP's exact receptor profile or can tolerate analog substitutions for the sake of practical dosing schedules.

Check receptor expression in your target tissue before concluding VIP is ineffective. VPAC1/VPAC2 density varies across cell types and disease states. Inflammatory conditions that downregulate VPAC receptors (documented in some chronic inflammation models) render tissues VIP-resistant regardless of dose. Dose-response curves are essential. VIP's receptor-mediated effects show a ceiling, and exceeding that ceiling doesn't increase efficacy. Timing matters equally: administering VIP after inflammatory cascades have fully activated may miss the intervention window. The peptide works best as a modulator during immune cell activation, not as a suppressor of established inflammation.

Reconstituted VIP stored at 2–8°C loses approximately 5–8% activity per week beyond the 14-day window due to deamidation and oxidation, even under ideal conditions. If your experimental design requires dosing over multiple weeks, aliquot the reconstituted solution into single-use volumes and store at −80°C. This extends stability to six months with <5% total activity loss. Thaw each aliquot only once, immediately before use, and never refreeze thawed solution. Alternatively, order smaller VIP quantities (1–2 mg per vial) that match your two-week dosing schedule, reconstitute only what you'll use in that window, and keep backup vials lyophilized at −20°C. The cost of ordering multiple small vials is always lower than the cost of failed experiments using degraded peptide from a single large vial stored too long.

Verify your administration technique first. Intranasal absorption depends on mucosal contact time, droplet size, and head positioning during delivery. Nasal lavage or rapid swallowing can clear VIP before absorption occurs. If technique is correct but effects are absent, consider anatomical variability in olfactory epithelium density or underlying inflammation that impairs mucosal permeability. Some research protocols use absorption enhancers (chitosan, cyclodextrins) to improve nasal bioavailability, though these additives must be controlled for separately. Plasma VIP measurements post-administration confirm whether the peptide reached systemic circulation. If levels don't rise, the issue is delivery; if they rise but CNS effects are absent, the issue is receptor availability or downstream signaling.

Contact the supplier immediately and request temperature-monitoring data if available. Reputable suppliers include temperature loggers or time-temperature indicators in shipments. VIP exposed to temperatures above 10°C for more than 24 hours during transit likely suffered partial denaturation, which manifests as reduced potency rather than total inactivity. If the supplier cannot verify cold-chain integrity, request a replacement vial before running experiments. Attempting to 'salvage' compromised peptide wastes both the peptide cost and the cost of your experimental time when results don't replicate. The best VIP supplier guarantees cold-chain shipping and replaces any vial that experienced documented temperature excursions at no cost. Anything less transfers the risk from supplier to researcher.

Plan for daily injections due to VIP's 1–2 minute half-life. No depot formulation exists for native VIP. Prepare aliquots of reconstituted peptide in single-use volumes to minimize freeze-thaw cycles, which denature the peptide. Consider using osmotic minipumps for continuous subcutaneous delivery if the protocol tolerates surgical implantation. This maintains stable plasma levels and reduces handling stress in animal models. Budget for higher peptide volumes than acute protocols require.